Modulating the effects of diabetes on osseointegration with aminoguanidine and doxycycline

Journal of Periodontology

Volumn 76, Issue 4, 2005, Pages 614-620

  Kopman, Jeffrey A ^a,b   Kim, David M ^b   Rahman, Suraiya S ^b,c   Arandia, Jason A ^a,b   Karimbux, Nadeem Y ^b   Fiorellini, Joseph P ^b  

^a Harvard School of Dental Medicine ^*

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Aminoguanidine therapeutic use; Animal studies; Dental implants; Diabetes mellitus; Doxycycline therapeutic use; Osseointegration; Wound healing

Indexed keywords

AMINOGUANIDINE; DOXYCYCLINE; TITANIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DRUG DOSE REGIMEN; DRUG RESPONSE; MALE; MEDICAL RESEARCH; NONHUMAN; RANDOMIZATION; RAT; RAT STRAIN; SURGICAL TECHNIQUE; TOOTH IMPLANTATION; TREATMENT OUTCOME; WOUND HEALING;

EID: 19044374984     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.4.614     Document Type: Article

References (40)

1. Mealey B. Diabetes and periodontol diseases. J Periodontol 1999;70:935-949.
2. Nevins ML, Karimbux NY, Weber HP, Giannobile WV, Fiorellini JP. Wound healing around endosseous implants in experimental diabetes. Int J Oral Maxillofac Implants 1998;13:620-629.
3. Takeshita F, Murai K, Iyama S, Ayukawa Y, Suetsugu T. Uncontrolled diabetes hinders bone formation around titanium implants in rat tibiae. A light and fluorescence microscopy, and image processing study. J Periodontol 1998;69:314-320.
4. Fiorellini JP, Nevins ML, Norkin A, Weber HP, Karimbux NY. The effect of insulin therapy on osseointegration in a diabetic rat model. Clin Oral Implant Res 1999;10:362-368.
5. Morris HF, Ochi S, Winkler S. Implant survival in patients with type 2 diabetes: Placement to 36 months. Ann Periodontol 2000;5:157-165.
6. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-526.
7. Golub LM, Ramamurthy NS, Kaneko H, Sasaki T, Rifkin B, McNamara TF. Tetracycline administration prevents diabetes-induced osteoponia in the rat: Initial observations. Res Commun Chem Pathol Pharmacol 1990;68:27-40.
8. Yu Z, Ramamurthy NS, Leung M, Chang KM, McNamara TF, Golub LM. Chemically-modified tetracycline normalizes collagen metabolism in diabetic rats: A dose-response study. J Periodontal Res 1993;28:420-428.
9. Paul RG, Bailey AJ. Glycation of collagen: The basis of its central role in the late complications of aging and diabetes. Int J Biochem Cell Biol 1996;28:1297-1310.
10. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996;11:931-937.
11. Bain S, Ramamurthy NS, Impeduglia T, Scolman S, Golub LM, Rubin C. Tetracycline prevents cancellous bone loss and maintains near-normal rates of bone formation in streptozotocin diabetic rats. Bone 1997;21:147-153.
12. Craig RG, Yu Z, Xu L, et al. A chemically modified tetracycline inhibits streptozocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA. Biochem Biophys Acta 1998;1402: 250-260.
13. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation. Bone 1998;22:33-38.
14. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: Role in the pathogenesis of diabetic complications. Clin Chem 1986;32(Suppl. 10):B37-B41.
15. Boel E, Selmer J. Flodgaard HJ, Jensen T. Diabetic late complications: Will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?. J Diabetes Complications 1995;9:104-129.
16. Brownlee M. Glycosylation products as toxic medicators of diabetic complications. Annu Rev Med 1991;42:159-166.
17. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-1843.
18. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
19. Li YM, Steffes M, Donnelly T. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci (USA) 1996;93:3902-3907.
20. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996;93:1905-1912.
21. Soulis T, Cooper ME, Vranes D, Bucala R, Jerum G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996;50:627-634.
22. Nakamura S, Makita Z, Ishikawa S. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997;46:895-899.
23. Tomasek JJ, Meyers SW, Basinger JB, Green DT, Shew RL. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life Sci 1994;55:855-861.
24. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: A puzzle nearing resolution. Diabetes 1996;45(Suppl. 3):S67-S72.
25. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
26. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases; a review. Crit Rev Oral Bio Med 1993; 4:197-250.
27. Matsumoto K, Ikeda K, Horiuchi S, Zhao H, Abraham EC. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem Biophys Res Commun 1997;241:352-354.
28. Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Curr Opin Periodontol 1994:111-118.
29. Kaneko H, Sasaki T, Ramamurthy NS, Golub LM. Tetracycline administration normalizes the structure and acid phosphatase activity of osteoclasts in streptozotocin-induced diabetic rats. Anat Rec 1990;227:427-436.
30. Sasaki T, Ramamurthy NS, Golub LM. Tetracycline administration increases collagen synthesis in osteoblasts of streptozocin-induced diabetic rats: A quantitative autoradiographic study. Calc Tissue Int 1992;50:411-419.
31. Rifkin BR, Vernillo AT, Golub LM, Ramamurthy NS. Modulation of bone resorption by tetracyclines. Ann NY Acad Sci 1994;732:165-180.
32. Donath K, Breuner G. A method for the study of undecalcified bones and teeth with attached soft tissues. The Sage-Schliff (sawing and grinding) technique. J Oral Pathol 1982;11:318-326.
33. Schenk RK, Olah AJ, Hermann W. Methods of Calcified Tissue Preparation. New York: Elsevier Science; 1984: 1-56.
34. Covington DS, X ue H, Pizzini R, Lally KP, Andrassy RJ. Streptozotocin and alloxan are comparable agents in the diabetic model of impaired wound healing. Diabetes Res 1993;23:47-53.
35. Goodman WG, Hori MT. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 1984;33:825-831.
36. Verhaeghe J, Suiker AM, Nyomba BL, et al. Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis. Endocrinology 1989;124:573-582.
37. Schenk RK, Buser D. Osseointegration: A reality. Periodontol 2000 1998;17:22-35.
38. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trials in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20:493-510.
39. Oturai PS, Rasch R, Hasselager E, et al. Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. APMIS 1996;104: 259-264.
40. Fong Y, Edelstein D, Wang EA, Brownlee M. Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. Diabetologia 1993;36:802-807.